SEATTLE, May 04, 2021, (PHARMIWEB) Overview:As a radioactive tracer, technetium-99m is used in nuclear medicine medical imaging procedures. It has a six-hour half-life and does not last long in the body or in the atmosphere. Tc-99m is primarily used in bone and brain scans using single photon emission computed tomo.
SEATTLE, May 04, 2021, (PHARMIWEB) Pain relief is provided by synthetic opioids. Synthetic opioids have a similar effect on the body as other opioids. Opioid receptor agonists function mainly on the brain and spinal cord in these drugs. Synthetic opioids have a greater effectiveness over most pain relievers, such a.
Search jobs 29-Apr-2021
SEATTLE, April 29, 2021, (PHARMIWEB) Overview:
Glaucoma is a category of diseases marked by optic nerve injury, visual field loss, and secondary retinal ganglion cell damage, both of which can result in death.
Glaucoma is the world’s second leading cause of blindness and the leading cause of permanent blindness globally, according to the International Agency for the Prevention of Blindness. Primary open angle glaucoma (POAG) and primary angle closure glaucoma (PACG) are the two most common forms of glaucoma. The chance of developing glaucoma rises with age, increased intraocular pressure, a favorable family history of glaucoma, and ethnicity.
Search jobs 12-Apr-2021 [2021] ALK Positive Lung Cancer Treatment Market Size Estimation, Future Growth Insights, Share Analysis, Key Profile, Dynamics and Business Overview By 2026
SEATTLE, April 12, 2021, (PHARMIWEB) ALK Positive Lung Cancer Treatment Market – Insights
Anaplastic Lymphoma Kinase (ALK) positive lung cancer is caused due to mutation of ALK, a gene that aids introduction of proteins. In the mutation, fusion of two genes called as ALK and Echinoderm Microtubule-associated protein Like 4 (EML4) leads to gene rearrangement. The ALK gene fusion was first reported in 2007, in non-small cell lung cancer (NSCLC) patients.
To learn more about this report, request a sample copy The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Search jobs 12-Apr-2021 [2021] Epidermolysis Bullosa Therapeutics Market Report Analysis, Global Size, Share, Industry Growth, Business Insight, Demand, Regional Analysis, Top Company Profile, Strategy Profiling, Challenges, Key Findings 2026
SEATTLE, April 12, 2021, (PHARMIWEB) Global Epidermolysis Bullosa (EB) Therapeutics Market
Epidermolysis Bullosa (EB) is a rare, genetic disorder of skin tissues. People suffering from EB have fragile skin, which is susceptible to blisters leading to wounds that are difficult to heal. Symptoms related to this disorder includes, blistering of skin, deformity or loss of fingernails and toenails, internal blistering including on the throat, esophagus, stomach, intestines and urinary tract, skin thickening on palms and soles of the feet (hyperkeratosis) and scalp blistering, scarring, and hair loss (scarring alopecia).